Brief: Cue Biopharma Presents Updated Data From Lead Program CUE-101 Cancer Treatment At SITC Meeting

Cue Biopharma

12/11/2021 14:23

Nov 12 (Reuters) - Cue Biopharma Inc  CUE.O :
    * CUE BIOPHARMA PRESENTS UPDATED DATA FROM LEAD PROGRAM
CUE-101
FOR THE TREATMENT OF RECURRENT/METASTATIC HPV+ HEAD AND NECK
CANCER AND ADDITIONAL PIPELINE PROGRESS AT THE SOCIETY FOR
IMMUNOTHERAPY OF CANCER’S (SITC) 36TH ANNUAL MEETING
    * CUE BIOPHARMA INC - EARLY CUE-101 COMBINATION DATA WITH
KEYTRUDA
(PEMBROLIZUMAB) SUPPORTS POTENTIAL MECHANISTIC ACTIVITY
    * CUE BIOPHARMA - CUE-102 IN VIVO DATA SHOWED ABILITY TO
SELECTIVELY ACTIVATE, EXPAND WT1-SPECIFIC T CELLS FOR TREATMENT
OF WT1-EXPRESSING CANCERS
    * CUE BIOPHARMA INC - CUE-102 IN VIVO DATA SUPPORTS CLINICAL
ADVANCEMENT OF CUE-102

Source text for Eikon:  ID:nGNX4xm9Bg 
Further company coverage:  CUE.O 

 ((Reuters.Briefs@thomsonreuters.com;))